ENVALITH
株式会社アドバネクス logo

Advanex Inc.

5998・Standard Market・Metal Products

Official website
株式会社アドバネクス logo
Advanex Inc.5998

Business

Advanex Inc. is a precision spring specialist manufacturer founded in 1930, operating manufacturing and sales of Precision Spring Products across four regions—Japan, Americas, Europe, and Asia—through 14 domestic and overseas consolidated subsidiaries. The company possesses diverse metal processing technologies including wire springs, flat springs, forming processing, insert molding, and deep drawing, supplying components to a wide range of industries such as automotive, medical, OA equipment, aircraft, and housing/infrastructure. Its major customers are automotive Tier 1 mega-suppliers and global pharmaceutical manufacturers (mega-pharma), and the company is expanding transactions with multinational leaders by leveraging its global supply system as a strength. Consolidated net sales for FY2026 (ending March 2026) were ¥29,680 million. Listed on the Standard Market of the Tokyo Stock Exchange.

Business Model

The company primarily operates on a build-to-order basis according to customer specifications, with sites in Japan, the Americas, Europe, and Asia handling manufacturing and sales in response to regional demand. Automotive applications account for more than half of sales, while medical and aircraft applications serve as growth drivers. The company also offers its own standard products such as Coil Thread, securing stable earnings in oligopolistic markets. In response to rising raw material and labor costs, the company has implemented price revisions (price increases) to improve profitability.

Company Strengths

The company has established itself as a rare Tier2 supplier capable of following the global procurement of Tier1 mega-suppliers, with 14 consolidated subsidiaries spanning Japan, the Americas (US, Mexico), Europe (UK, Czech Republic), and Asia (Thailand, Vietnam, Indonesia, India, China, Singapore, etc.). This network is described in the securities report as outstanding among precision metal processing manufacturers.

Coil Thread, the company's core proprietary product, is seeing expanding demand centered on the aviation market and occupies a position in an oligopolistic market with limited competitors globally. In addition, the anti-loosening products "Lock One" and "Instant Lock" are gaining increasing recognition in the infrastructure and housing equipment markets. This proprietary product lineup, which does not rely on made-to-order products, contributes to revenue diversification.

While automotive applications account for more than half of sales, the company is expanding into medical applications (springs for pharmaceutical kits for mega-pharma companies) and aircraft applications. In FY2026 (ending March 2026), medical applications drove an 11.2% year-on-year increase in revenue and a 43.4% increase in segment profit in the Americas segment, while the Asia segment also achieved a 28.7% increase in segment profit driven by strong automotive and precision equipment applications. This diversification across multiple markets contributes to earnings stability.

ENVALITH's Perspective

In the corrected earnings report dated June 2, 2026, non-consolidated (standalone) net income for the period was revised down by approximately 58%, from ¥196 million pre-correction to ¥82 million. The main causes were an increase in the provision for doubtful accounts (from ¥211 million pre-correction to ¥326 million post-correction) and a significant reduction in pre-tax net income (from ¥123 million to ¥8 million). With the balance of long-term loans receivable from affiliated companies swelling to ¥4,237 million, the provision for doubtful accounts was also increased from ¥295 million to ¥410 million, warranting continued close attention to trends in intra-group credit management.

Consolidated operating profit for FY2026 (ending March 2026) recovered to a five-period high of ¥1,323 million, and net sales achieved a fifth consecutive year of growth at ¥29,680 million. On the other hand, due to capital expenditures such as the construction of a new plant in Thailand, cash flow from investing activities resulted in an outflow of ¥2,867 million (post-correction), and ¥5,353 million in new long-term borrowings was also raised. Cash flow from financing activities was limited to an inflow of ¥1,285 million, and the balance of borrowings continues to increase. Together with the declining trend in the equity ratio, the pace of depletion of financial capacity warrants continued careful monitoring.

Expanding orders for medical applications in the Americas and Europe segments, as well as demand for automotive and OA equipment applications in the Asia segment, have been confirmed as actual results and can be evaluated as medium-term growth drivers. However, there is an aspect in which the benefit of a weaker yen and stronger dollar, an external factor, is supporting performance, and the impact on earnings from foreign exchange fluctuations (foreign exchange gains in operating cash flow were revised from a gain of ¥490 million to a gain of ¥324 million post-correction) and changes in U.S. tariff policy remain significant risk factors going forward.

Growth Strategy

Accelerating global expansion across three pillars—medical, automotive, and standard products—while aiming to strengthen the profit structure

Centered on expanding spring adoption in pharmaceutical kits for major Western pharma companies, the company is enhancing medical-use production at its U.S., Czech, and Japan sites. The U.S. plant has already turned profitable, while the Czech plant is transitioning to a full-scale mass production phase, with the aim of raising the global share of medical-related sales.

A new plant is under construction in Thailand to meet growing demand in the Asia segment. In FY2026 (ending March 2026), capital expenditure for property, plant and equipment of ¥2,963 million (revised figure) was recorded; upon completion, the company expects an increase in production capacity for automotive and OA equipment applications and a full-scale contribution to earnings.

The company is expanding its standard products business, centered on Coil Thread, which faces limited competition, into the aviation market, cultivating it as a stable revenue source that complements the volatility risk of the build-to-order manufacturing model. Order intake continues on an increasing trend, and sales expansion efforts will continue.

The company continues to drive profitability improvement at its Mexico plant, aiming to raise the profit margin across the Americas segment as a whole. The U.S. plant has already turned profitable through medical-related expansion. Steady improvement at the Mexico plant has also been confirmed on a cumulative basis through 3Q of FY2026 (ending March 2026), and the company aims to stabilize profitability across the entire Americas segment.

Last updated: July 19, 2026